Table 1.
Ongoing Or Planned Clinical Trials Of Midostaurin In AML
| # | NCT Number | Other Identifiers | Indication | Start Date | Status | Phase |
|---|---|---|---|---|---|---|
| 1 | NCT03951961 | MAURITIUS | Midostaurin in MRD positive AML post- allogeneic SCT | July 1, 2019 | Not yet recruiting | II |
| 2 | NCT03900949 | NCI-2019-01726 | Standard induction with GO and Midostaurin in newly diagnosed FLT3-mutated AML | March 21, 2019 | Recruiting | I |
| 3 | NCT03836209 | PrE0905 | Gilteritinib vs Midostaurin in FLT3-mutated newly diagnosed AML | July 2019 | Not yet recruiting | II |
| 4 | NCT03686345 | REL-AML 001/2017 | Midostaurin with standard chemotherapy in CBF leukemia | July 1, 2018 | Recruiting | II |
| 5 | NCT03591510 | CPKC412A2218 | Midostaurin + chemotherapy in pediatric newly diagnosed FLT3-mutated AML (global study) | March 13, 2019 | Recruiting | II |
| 6 | NCT03512197 | CPKC412E2301 | Midostaurin + chemotherapy in newly diagnosed FLT3 wildtype AML (global study) | January 7, 2018 | Recruiting | III |
| 7 | NCT03379727 | CPKC412A2408 | Midostaurin + chemotherapy in induction and consolidation followed by 12 months of maintenance monotherapy in newly diagnosed FLT3-mutated AML. | February 13, 2018 | Recruiting | III |
| 8 | NCT03280030 | CPKC412A2220 | Midostaurin + chemotherapy in induction and consolidation followed by maintenance monotherapy in newly diagnosed FLT3-mutated AML | April 6, 2018 | Recruiting | II |
| 9 | NCT03258931 | ARO-021 | Crenolanib vs Midostaurin with induction and consolidation in newly diagnosed FLT3-mutated AML | August 15, 2018 | Recruiting | III |
| 10 | NCT02634827 | MC1483 | Midostaurin + Decitabine in newly diagnosed elderly (>60yr) FLT3-mutated AML | December 30, 2015 | Active, not recruiting | II |
| 11 | NCT01830361 | TUD-MIDOKI-052 | Midostaurin + chemotherapy in c-KIT or FLT3-mutated t(8;21) AML | April 2012 | Active, not recruiting | II |
| 12 | NCT01477606 | AMLSG 16-10 | Midostaurin + chemotherapy in induction and consolidation followed by maintenance in FLT3-ITD AML | May 2012 | Active, not recruiting | II |
| 13 | NCT00819546 | 08-269 | Midostaurin + Everolimus in R/R AML or MDS | January 2009 | Active, not recruiting | I |
| 14 | NCT00651261 | CALGB-10,603 | Midostaurin + chemotherapy in newly diagnosed AML | April 2008 | Active, not recruiting | III |
Abbreviations: FLT3, FMS-like tyrosine kinase; MRD, minimal residual disease; AML, acute myeloid leukemia; SCT, stem cell transplantation; GO, Gemtuzumab ozogamicin; CBF, core binding factor; R/R, relapsed/refractory.